Sections & Workgroups > Section on Medicines Development
Section on Medicines Development
With the mapping of the human genome, biotechnology is of increasing importance for development of new and targeted medicines and will impact future medical practice. This calls for an optimising of the current medicines R&D process and a re-thinking of the process. It is for this reason that the Section on Medicines Development was established in 2003. This Section covers all aspects of Medicines Development (which today all will involve biotech in one way or other) as well as all processes within the R&D cycle from idea through research, applied research, preclinical, clinical, regulatory and post-marketing follow-up.
The EFB Section on Medicines Development is a platform for all stakeholders and sciences related to development of medicines. NSMF follows two tracks:
Streamlining:
Activities to optimise and reengineer the current drug research & development processes utilising contemporary scientific knowledge by removing bottlenecks and developing new tools.
Fresh approach:
To re-evaluate the entire drug development process and create a new efficient flow of knowledge generation and management without compromising safety based on recent scientific and technological advances including genome research.
NSMF enjoys strong support from EC DG Research as well as from EUREKA. A steadily increase in members of the section is reflecting that also universities, hospitals, medicines agencies, pharmaceutical companies, and SMEs from most countries in Europe are interested in engaging in this major and strategic initiative. NSMF webpage (www.nsmf.org) provides information about NSMF including an overview of NSMF, reports from workshops, and NSMF relevant events and activities.
For information about the activities of this Section please contact:
Dr. Jorgen Dirach, MD, MBA, MFPM (Chairman)
Novo Nordisk A/S, Corporate Research Affairs
Novo Alle 1
DK-2880 Bagsvaerd, DK
Phone +45 4442 3355
Fax +45 4442 1286
E-mail: jdi@novonordisk.com